<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med Exp</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med Exp</journal-id><journal-title-group><journal-title>Intensive Care Medicine Experimental</journal-title></journal-title-group><issn pub-type="epub">2197-425X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4798147</article-id><article-id pub-id-type="publisher-id">963</article-id><article-id pub-id-type="doi">10.1186/2197-425X-3-S1-A823</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>High flow conditioned oxygen therapy for prevention of reintubation in critically ill patients at high risk for extubation failure: a multicenter randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hernandez</surname><given-names>G</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Vaquero</surname><given-names>C</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Gonzalez</surname><given-names>P</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Colinas</surname><given-names>L</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Garcia</surname><given-names>S</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Canabal</surname><given-names>A</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Villasclaras</surname><given-names>A</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Cuena</surname><given-names>R</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Fernandez</surname><given-names>R</given-names></name><xref ref-type="aff" rid="Aff5"/><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Complejo Hospitalario de Toledo, Intensive Care Medicine, Toledo, Spain </aff><aff id="Aff2"><label/>Hospital Universitario Ramon y Cajal, Intensive Care Medicine, Madrid, Spain </aff><aff id="Aff3"><label/>Hospital Universitario Infanta Sofia, Intensive Care Medicine, San Sebastian de los Reyes, Spain </aff><aff id="Aff4"><label/>Medical Council, Research Unit, Toledo, Spain </aff><aff id="Aff5"><label/>Hospital Sant Joan de Deu-Fundaci&#x000f3; Althaia, Intensive Care Medicine, Manresa, Spain </aff><aff id="Aff6"><label/>Universitat Internacional de Catalunya. CIBERES, Manresa, Spain </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 1</issue><issue-sponsor>The publication charges for this supplement were funded by Intensive Care Medicine Experimental.</issue-sponsor><elocation-id>A823</elocation-id><permissions><copyright-statement>&#x000a9; Hernandez et al.; 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><conference><conf-name>ESICM LIVES 2015</conf-name><conf-loc>Berlin, Germany</conf-loc><conf-date>3-7 October 2015</conf-date><string-conf><uri>http://www.esicm.org/</uri></string-conf></conference><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Critically ill mechanically ventilated patients are usually stratified in two levels according to the risk for reintubation. In low-risk patients high flow conditioned oxygen therapy (HFO) may reduce reintubation, whereas in high-risk patients non-invasive mechanical ventilation (NIMV) to prevent reintubation is gaining acceptance. However, data on the efficacy or safety of HFO in high-risk patients are lacking.</p></sec><sec id="Sec2"><title>Objectives</title><p>We hypothesized that HFO is an appropriate alternative to NIMV in preventing reintubation in high risk patients. The primary outcome was all-causes and respiratory-related reintubation rate within 72 hours.</p></sec><sec id="Sec3"><title>Methods</title><p>In this multicenter, randomized, noninferiority trial, we recruited 603 critically ill patients at high-risk for reintubation to be treated after extubation with either HFO (n = 290) or NIMV (n = 313). High-risk for reintubation was defined as the presence of at least any of the following criteria: &#x0003e;65 years, cardiac failure, moderate-to-severe COPD, APACHE II &#x0003e;12 points at extubation day, body mass index &#x0003e;30, airway patency problems, inadequate secretions management, not simple weaning, &#x02265;2 comorbidities, and prolonged mechanical ventilation. NIMV as a rescue therapy was not allowed in the HFO group. Noninferiority was determined as a &#x0003c; 6% absolute difference in the risk of the primary outcome.</p></sec><sec id="Sec4"><title>Results</title><p>Respiratory-related reintubations occurred in 49 (16.9%) HFO patients and in 50 (16%) NIMV patients (risk difference 0.9%; upper limit of the unilateral 95%CI 5.9). All-causes reintubation occurred in 67 (23.1%) HFO patients and in 60 (19.2%) NIMV patients (risk difference 3.9%; upper limit of the unilateral 95%CI 9.4%).</p></sec><sec id="Sec5"><title>Conclusions</title><p>In critically ill patients at high risk, HFO was noninferior to NIMV in preventing respiratory-related reintubation, but not all-causes reintubation. The study was registered at ClinicalTrials.gov (Identifier: NCT01191489).</p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maggiore</surname><given-names>SM</given-names></name><name><surname>Idone</surname><given-names>FA</given-names></name><name><surname>Vaschetto</surname><given-names>R</given-names></name><etal/></person-group><article-title>Nasalhigh-flow versus venture mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome</article-title><source>Am J Respir Crit Care Med</source><year>2014</year><volume>190</volume><fpage>282</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1164/rccm.201402-0364OC</pub-id><pub-id pub-id-type="pmid">25003980</pub-id></element-citation></ref></ref-list></back></article>